As of 2025-09-18, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -28.84. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 16,588.49 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-09-16 | -28.89 |
| 2025-09-15 | -30.22 |
| 2025-09-12 | -30.22 |
| 2025-09-11 | -29.67 |
| 2025-09-10 | -28.06 |
| 2025-09-09 | -30.04 |
| 2025-09-08 | -31.04 |
| 2025-09-05 | -41.65 |
| 2025-09-04 | -38.11 |
| 2025-09-03 | -37.66 |
| 2025-09-02 | -38.18 |
| 2025-08-29 | -37.95 |
| 2025-08-28 | -39.12 |
| 2025-08-27 | -39.74 |
| 2025-08-26 | -43.27 |
| 2025-08-25 | -42.12 |
| 2025-08-22 | -42.01 |
| 2025-08-21 | -41.70 |
| 2025-08-20 | -41.47 |
| 2025-08-19 | -40.63 |
| 2025-08-18 | -42.15 |
| 2025-08-15 | -42.80 |
| 2025-08-14 | -42.41 |
| 2025-08-13 | -43.09 |
| 2025-08-12 | -41.17 |
| 2025-08-11 | -45.33 |
| 2025-08-08 | -46.00 |
| 2025-08-07 | -45.04 |
| 2025-08-06 | -45.77 |
| 2025-08-05 | -46.76 |
| 2025-08-04 | -47.07 |
| 2025-08-01 | -43.42 |
| 2025-07-31 | -42.28 |
| 2025-07-30 | -42.75 |
| 2025-07-29 | -42.88 |
| 2025-07-28 | -44.04 |
| 2025-07-25 | -46.02 |
| 2025-07-24 | -44.23 |
| 2025-07-23 | -44.94 |
| 2025-07-22 | -42.56 |
| 2025-07-21 | -42.23 |
| 2025-07-18 | -42.01 |
| 2025-07-17 | -44.33 |
| 2025-07-16 | -45.37 |
| 2025-07-15 | -39.02 |
| 2025-07-14 | -40.71 |
| 2025-07-11 | -40.06 |
| 2025-07-10 | -41.49 |
| 2025-07-09 | -39.64 |
| 2025-07-08 | -36.80 |